Form 4: Vertex Pharma EVP Sells Shares for Tax Obligations

Vertex Pharmaceuticals' EVP, Chief Operating Officer, and Chief Financial Officer, Charles F. Wagner Jr., disposed of 1,744 shares of common stock to cover tax withholding obligations.

Summary

• Charles F. Wagner Jr., Executive Vice President, Chief Operating Officer, and Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), reported a transaction involving the company's common stock.
• On February 24, 2026, Wagner disposed of 1,744 shares of common stock.
• The disposition was made at a price of $485.11 per share.
• This transaction was identified as a disposition to the issuer to satisfy tax withholding obligations (Transaction Code 'F').
• Following this transaction, Wagner directly beneficially owns 47,042 shares of Vertex Pharmaceuticals common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine administrative transaction for tax purposes rather than a discretionary sale or purchase that would signal management's view on the company's prospects.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-arranged and systematic approach to managing equity compensation, which can reduce concerns about opportunistic insider trading.

Negatives

• No specific negative implications are apparent from this routine tax-related disposition.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that routine insider transactions, particularly those for tax withholding purposes and executed under Rule 10b5-1 plans, are common across the pharmaceutical and biotechnology industries as a standard practice for executives managing their equity compensation. This transaction does not indicate any specific industry trend or competitive move.

Comparison to Industry Standards

• This transaction is a standard disposition of shares to cover tax obligations, a common practice for executives receiving equity compensation across all industries.
• It aligns with typical corporate governance practices for managing executive stock awards and does not present any unusual deviations from global benchmarks.

Related Party Transactions

• The disposition of shares to the issuer to satisfy tax withholding obligations is a form of related party transaction between an executive and the company.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes. It does not signal a change in the executive's confidence in the company.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by an executive to cover tax withholding obligations, executed under a Rule 10b5-1 plan. Such transactions are administrative in nature and do not typically reflect a change in the executive's outlook on the company's fundamentals or future performance. Therefore, it provides no new information that would warrant a change in investment recommendation. Investors should continue to hold based on broader company performance and market conditions.

Keywords

Vertex Pharmaceuticals, VRTX, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Charles F. Wagner Jr., Executive Compensation, Rule 10b5-1